Magurol

Doxazosin, the active ingredient in Magurol, is a Alpha-1 adrenergic blocker presented as an oral dosage form for oral use. It is indicated for the management of hypertension and for relief of urinary symptoms caused by benign prostatic hyperplasia in adult patients.

GNH USA supplies Magurol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin belongs to the alpha‑1 adrenergic blocker class and is used to treat conditions related to vascular tone and prostatic enlargement.

- Hypertension: lowers systemic blood pressure by relaxing peripheral arterial smooth muscle. - Benign prostatic hyperplasia (BPH): improves urinary flow by reducing smooth‑muscle tone in the prostate and bladder neck. - Lower urinary tract symptoms due to BPH: decreases urgency, frequency and nocturia associated with prostatic enlargement.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or generalized weakness. - Nasal congestion or rhinorrhea. - Peripheral edema.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Tachycardia or arrhythmia. - Allergic reactions such as rash, pruritus or angioedema. - Liver function abnormalities. - Priapism (rare).

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: check orthostatic readings after the first dose. - Renal or hepatic impairment: adjust therapy based on organ function. - Concomitant antihypertensives: assess for additive hypotensive effect. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other potent antihypertensives (e.g., ACE inhibitors, ARBs) – risk of excessive blood pressure drop. - Potassium‑sparing diuretics – may enhance hypotensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole) – increase plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive response. - Beta‑blockers – combined effect on heart rate and blood pressure. - Alcohol – can potentiate dizziness and hypotension.